The cytotoxicity studies of these novel compounds have been conducted in vitro against three different tumour cell lines: MCF-7topo (multidrug-resistant breast cancer), HCT-116wt, and the p53 knockout mutant HCT-116−/− (colon cancer). This evidence concerns the gene TP53 and breast carcinoma.